ClinicalTrials.gg
Not yet recruitingNCT07190391Updated Sep 24, 2025

Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis

An observational study in Psoriasis, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
425
Ages
19 Years and older
Sex
All
01

Study summary

This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.

Read the detailed description

In this clinical trial, patients with psoriasis will be informed about study participation and written informed consent will be obtained voluntarily. Eligible participants, based on inclusion and exclusion criteria, will be assigned a registration number. Participants will receive Apremilast for 32 weeks and visit the study site at three time points: Visit 1 (screening and baseline, Week 0), Visit 2 (Week 16 ± 4), and Visit 3 (Week 32 ± 4). At each visit, demographic information, efficacy assessments, and adverse event evaluations will be conducted according to the study schedule.

02

Conditions studied

  • Psoriasis

Browse trials for

03

In context

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

This study's planned enrollment of 425 is above the median of 200 across 408 observational studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

In the ESTEEM 1 study of moderate-to-severe psoriasis, 33.1% of patients achieved PASI 75 at Week 16 with apremilast, while 28.8% did so in ESTEEM 2. Based on these results, this trial assumed a Week 16 PASI 75 response rate of \~30%. To estimate this with a 95% confidence interval and ±5% margin of error, a sample size of 340 was calculated. If the observed rate is 30%, the Clopper-Pearson method yields a lower bound of 25.2%. The study aims to present the Week 16 PASI 75 response rate with 95% confidence in a single-arm design, ensuring effect size and precision. Considering \~20% dropout, 425 subjects will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥19 years at the time of enrollment.
  • Patients with moderate to severe psoriasis persisting for ≥6 months.
  • Patients with a PASI (Psoriasis Area and Severity Index) score between 5 and 10, requiring pharmacological treatment.
  • Patients who have been fully informed about the study, have understood the explanation, and have voluntarily signed the form.
  • Patients who are considered cooperative and able to participate until the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of to apremilast.
  • Patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  • Pregnant or breastfeeding women.
  • Patients (or their spouse/partner) who do not agree to use medically acceptable and appropriate methods of * during the study period.

    * Medically acceptable and appropriate methods of contraception include: hormonal contraception (implants, injectables, oral contraceptives, etc.), intrauterine devices (copper IUD, hormone-releasing intrauterine system), salpingectomy, tubal ligation, hysterectomy, vasectomy, dual barrier methods (male condom and female condom, cervical cap, diaphragm, contraceptive sponge used in combination), or single barrier method combined with spermicide.

  • Patients receiving strong enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin, St. John's Wort).
  • Patients with severe renal impairment requiring hemodialysis or peritoneal dialysis.
  • Patients who have previously received Apremilast (ApsoLla®) prior to enrollment, or those currently participating in another clinical trial involving an medicinal product or medical device.

(However, patients enrolled in non-interventional studies or who have completed participation in another clinical trial are eligible.)

  • Patients with a history of psychiatric disorders (e.g., substance abuse, depression).
  • Patients who, in the opinion of the investigator, are otherwise considered unsuitable for participation in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
425 participants (estimated)
Patient registry
No

Groups and cohorts

  • Apsola Tab.

    Apsola Tab. 10mg, Apsola Tab. 20mg, Apsola Tab. 30mg

06

What researchers measure

Primary outcomes

  1. Proportion of patients who achieved PASI 75

    Proportion of patients who achieved PASI 75 at week 16

    Time frame: 16 weeks

Secondary outcomes

  1. [Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 75

    Proportion of patients who achieved PASI 75 at week 32

    Time frame: 32 weeks

  2. [Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 50

    Proportion of patients who achieved PASI 50 at weeks 16

    Time frame: 16 weeks

  3. [Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 50

    Proportion of patients who achieved PASI 50 at weeks 32

    Time frame: 32 weeks

  4. [Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 90

    Proportion of patients who achieved PASI 90 at weeks 16

    Time frame: 16 weeks

  5. [Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 90

    Proportion of patients who achieved PASI 90 at weeks 32

    Time frame: 32 weeks

  6. [Investigator-Assessed Endpoints]Proportion of patients with an absolute PASI score ≤ 2

    Proportion of patients with an absolute PASI score ≤ 2 at weeks 16

    Time frame: 16 weeks

  7. [Investigator-Assessed Endpoints]Proportion of patients with an absolute PASI score ≤ 2

    Proportion of patients with an absolute PASI score ≤ 2 at weeks 32

    Time frame: 32 weeks

  8. [Investigator-Assessed Endpoints]Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index)

    Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index) from baseline at weeks 16

    Time frame: 16 weeks

  9. [Investigator-Assessed Endpoints]Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index)

    Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index) from baseline at weeks 32

    Time frame: 32 weeks

  10. [Investigator-Assessed Endpoints]Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1

    Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1 at weeks 16

    Time frame: 16 weeks

  11. [Investigator-Assessed Endpoints]Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1

    Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1 at weeks 32

    Time frame: 32 weeks

  12. [Patient-Reported Endpoints]Change from baseline in DLQI (Dermatology Life Quality Index)

    Change from baseline in DLQI (Dermatology Life Quality Index) at weeks 16

    Time frame: 16 weeks

  13. [Patient-Reported Endpoints]Change from baseline in DLQI (Dermatology Life Quality Index)

    Change from baseline in DLQI (Dermatology Life Quality Index) at weeks 32

    Time frame: 32 weeks

  14. [Patient-Reported Endpoints]Change from baseline in Pruritus NRS (Numeric Rating Scale)

    Change from baseline in Pruritus NRS (Numeric Rating Scale) at weeks 16

    Time frame: 16 weeks

  15. Change from baseline in Pruritus NRS (Numeric Rating Scale)

    Change from baseline in Pruritus NRS (Numeric Rating Scale) at weeks 32

    Time frame: 32 weeks

  16. [Patient-Reported Endpoints]Change from baseline in PaGA (Patient Global Assessment)

    Change from baseline in PaGA (Patient Global Assessment) at weeks 16

    Time frame: 16 weeks

  17. [Patient-Reported Endpoints]Change from baseline in PaGA (Patient Global Assessment)

    Change from baseline in PaGA (Patient Global Assessment) at weeks 32

    Time frame: 32 weeks

  18. [Patient-Reported Endpoints]Shift in distribution of PaGA scores

    Shift in distribution of PaGA scores from baseline at weeks 16

    Time frame: 16 weeks

  19. [Patient-Reported Endpoints]Shift in distribution of PaGA scores

    Shift in distribution of PaGA scores from baseline at weeks 32

    Time frame: 32 weeks

  20. [Patient-Reported Endpoints]Proportion of patients who achieved PaGA score of 0 or 1

    Proportion of patients who achieved PaGA score of 0 or 1 at weeks 16

    Time frame: 16 weeks

  21. [Patient-Reported Endpoints]Proportion of patients who achieved PaGA score of 0 or 1

    Proportion of patients who achieved PaGA score of 0 or 1 at weeks 32

    Time frame: 32 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 15 months is below that.

Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 24, 2025
StartEst.
Sep 30, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Oct 31, 2027
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07190391
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Sep 30, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Sep 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion